{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:37:35Z","timestamp":1761100655118},"reference-count":4,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,3,1]]},"DOI":"10.1182\/blood-2003-10-3612","type":"journal-article","created":{"date-parts":[[2004,2,18]],"date-time":"2004-02-18T20:18:23Z","timestamp":1077135503000},"page":"1968-1968","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":53,"title":["Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure"],"prefix":"10.1182","volume":"103","author":[{"given":"Brigitta","family":"Versluys","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajat","family":"Bhattacharaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin","family":"Steward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jackie","family":"Cornish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Oakhill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Goulden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021218105788700_REF1","doi-asserted-by":"crossref","unstructured":"Wadleigh M, Ricahrdson P, Zahrieh D, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003; 102: 1578-1582.","DOI":"10.1182\/blood-2003-01-0255"},{"key":"2020021218105788700_REF2","doi-asserted-by":"crossref","unstructured":"Bearman S. Don't GO to VOD. Blood. 2003;102: 1561-1562.","DOI":"10.1182\/blood-2003-06-2100"},{"key":"2020021218105788700_REF3","doi-asserted-by":"crossref","unstructured":"Webb DK, Harrison G, Stevens RF, et al. Relationships between age at diagnosis, clinical features, and outcome therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukaemia. Blood. 2001;98: 1714-1720.","DOI":"10.1182\/blood.V98.6.1714"},{"key":"2020021218105788700_REF4","doi-asserted-by":"crossref","unstructured":"McCarthy AJ, Pitcher LA, Hann IM, Oakhill A. FLAG for refractory and high risk acute leukaemia in children. Med Paediatr Oncol. 1999;32: 411-415.","DOI":"10.1002\/(SICI)1096-911X(199906)32:6<411::AID-MPO3>3.0.CO;2-K"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/5\/1968\/1696252\/zh800504001965c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/5\/1968\/1696252\/zh800504001965c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T19:18:32Z","timestamp":1581535112000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/103\/5\/1968\/18191\/Prophylaxis-with-defibrotide-prevents"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3,1]]},"references-count":4,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,3,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-10-3612","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3,1]]}}}